Nanoliposomal Irinotecan hydrochloride

盐酸伊立替康纳米脂质体

Report date: 2026/05/22 20:01:29

Base Information

Drug NameNanoliposomal Irinotecan hydrochloride
Drug Alias Name伊立替康脂质体Nanoliposomal irinotecan injection - Merrimack/PharmaEngineNanoliposomal irinotecan - Merrimack/PharmaEnginepegylated liposomal irinotecan hydrochloride trihydrateIrinotecan liposome injection - Merrimack +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsGastroenteropancreatic neuroendocrine tumorSolid tumoursAscites +[6] 
Global Approved IndicationsPancreatic Neoplasms
Approved Indications in ChinaPancreatic Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2015/10/22
Country/TerritoryBelgiumUnited StatesUkraine +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHERMES Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesCSPC Pharmaceutical Group LtdNational Health Research InstitutesMerrimack Pharmaceuticals Inc +[9] 
Inactive CompaniesPharmaengine Inc
Active IndicationsGastroenteropancreatic neuroendocrine tumorSolid tumoursAscites +[5] 
Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeL01CE02
Related LinksDrugBankKEGG